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Abstract
Background: Gab1 is a docking protein that recruits phosphatidylinositol-3 kinase (PI-3 kinase)
and other effector proteins in response to the activation of many receptor tyrosine kinases (RTKs).
As the autophosphorylation sites on EGF-receptor (EGFR) do not include canonical PI-3 kinase
binding sites, it is thought that EGF stimulation of PI-3 kinase and its downstream effector Akt is
mediated by an indirect mechanism.
Results: We used fibroblasts isolated from Gab1-/- mouse embryos to explore the mechanism of
EGF stimulation of the PI-3 kinase/Akt anti-apoptotic cell signaling pathway. We demonstrate that
Gab1 is essential for EGF stimulation of PI-3 kinase and Akt in these cells and that these responses
are mediated by complex formation between p85, the regulatory subunit of PI-3 kinase, and three
canonical tyrosine phosphorylation sites on Gab1. Furthermore, complex formation between Gab1
and the protein tyrosine phosphatase Shp2 negatively regulates Gab1 mediated PI-3 kinase and Akt
activation following EGF-receptor stimulation. We also demonstrate that tyrosine phosphorylation
of ErbB3 may lead to recruitment and activation of PI-3 kinase and Akt in Gab1-/- MEFs.
Conclusions: The primary mechanism of EGF-induced stimulation of the PI-3 kinase/Akt anti-
apoptotic pathway occurs via the docking protein Gab1. However, in cells expressing ErbB3, EGF
and neuroregulin can stimulate PI-3 kinase and Akt activation in a Gab1-dependent or Gab1-
independent manner.
Background
Ligand stimulation of the epidermal growth factor recep-
tor (EGFR) and the three other members of the EGFR fam-
ily of receptor tyrosine kinases (ErbB2, ErbB3 and ErbB4)
results in tyrosine autophosphorylation, recruitment of
signaling proteins, and activation of distinct complement
of signaling pathways that regulate a great variety of cellu-
lar responses [1,2].
One of the signaling pathways that is activated by the
EGFR is the phosphatidylinositol-3 kinase (PI-3 kinase)/
Akt anti-apoptic signaling pathway [3]. The PI-3 kinase
holoenzyme consists of a regulatory subunit (p85) and a
catalytic p110 subunit. The regulatory subunit contains
two SH2 domains that bind specifically to pYXXM motifs
in a variety of cellular proteins, including receptor tyro-
sine kinases such as the PDGF (platelet-derived growth
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factor) receptor, and c-kit and docking proteins such as
IRS (insulin receptor substrate) 1, IRS2 and Gab1.
Although the cytoplasmic domain of the EGFR does not
contain any canonical p85 binding motifs, EGF stimula-
tion leads to PI-3 kinase activation by an indirect mecha-
nism. It has been proposed that the PI-3 kinase is
activated in response to EGF stimulation as a consequence
of formation of EGFR/ErbB3 heterodimers [4]. Unlike
EGFR, the cytoplasmic region of ErbB3 contains at least
six pYXXM motifs [5,6]. Indeed, EGF stimulation of cells
co-expressing the EGFR and ErbB3 results in recruitment
and activation of PI-3 kinase by tyrosine phosphorylated
ErbB3 [4].
EGF stimulation of PI-3 kinase may also be mediated by
the docking protein Gab1 (Grb2-associated binder-1).
EGF stimulation leads to tyrosine phosphorylation of
Gab1 enabling recruitment and activation of PI-3 kinase
by the three canonical pYXXM motifs on Gab1 [7]. Gab1
was originally identified as a Grb2 binding protein, and
was shown to be tyrosine phosphorylated in response to
treatment with a variety of growth factors [7-9]. Gab1 con-
tains a number of tyrosine residues that could serve as
potential binding sites for the SH2 domain containing
proteins Grb2, PI-3 kinase, and the protein tyrosine phos-
phatase Shp2 [10]. While there have been reports that
Gab1 binds directly to the EGFR via an 83-amino acid
stretch termed the Met-binding-domain or MBD [9], the
majority of Gab1 is believed to be indirectly associated
with the EGFR via the adaptor protein Grb2, which binds
to a proline rich region on Gab1 via its C-terminal SH3
domain [10-13].
Cells over-expressing a mutant Gab1 protein containing
tyrosine to phenylalanine mutations at the three p85
binding sites have been shown to be defective in EGF-
induced JNK activation, and treatment of cells over-
expressing wild type Gab1 with PI-3 kinase inhibitors
interferes with MAPK signaling in response to EGF treat-
ment, thus revealing a link between Gab1 and PI-3 kinase
in EGF-induced mitogenic signaling [9,14]. Furthermore,
the PI-3 kinase product phosphatidylinositol (3,4,5) tri-
phosphate (PIP3) has been shown to bind to the pleck-
strin homology (PH) domain of Gab1 resulting in
membrane-association of Gab1, suggesting a positive
feedback loop in which PI-3 kinase acts as both an
upstream regulator and a downstream effector of Gab1
signaling via the EGFR [9]. Gab1 thus acts as a docking
protein facilitating the recruitment of a multi-protein sig-
naling complex including the EGFR, p85 and Shp2 in
response to EGF treatment.
Although the role of the Shp2 protein in the control of
EGFR/Gab1 interactions is not well understood, several
studies have suggested that Gab1-associated Shp2 may
influence EGF-induced PI-3 kinase signaling. Previous
work has shown that Gab1 is not a global substrate of
Shp2, as complex formation between Gab1 and Shp2
does not reduce the total EGF-induced tyrosine phospho-
rylation levels of Gab1 [15]. However there have been sev-
eral reports suggesting that Shp2 may specifically de-
phosphorylate the tyrosine phosphorylation sites on
Gab1 that bind to p85, thus terminating recruitment of
PI-3 kinase and EGF-induced activation of the PI-3 kinase
pathway [16-18]. It has been shown that cells devoid of
Shp2 show an increase in PI-3 kinase activity, as well as
elevated and sustained levels of Akt activation in response
to EGF treatment [18]. It was reported that treatment of
cells with PI-3 kinase inhibitors or with the phosphati-
dylinositol (3,4,5) triphosphate (PIP3) phosphatase
PTEN interferes with the association between Gab1 and
Shp2 in response to EGF treatment, suggesting PI-3 kinase
may be required for Shp2 recruitment of Gab1 following
EGF stimulation [14]. However, the mechanism for this
postulated recruitment is unknown.
In the experiments presented here we utilized fibroblasts
isolated from Gab1-/- mouse embryos in order to exam-
ine the role of Gab1 in EGF-mediated activation of the PI-
3 kinase/Akt cell survival pathway. We also address the
question of whether ErbB3 recruitment of PI-3 kinase is
dependent on or independent of Gab1. Our results dem-
onstrate a clear requirement for Gab1 in recruitment and
activation of PI-3 kinase in response to EGF stimulation.
Additionally, we show that while Shp2 does not mediate
global dephosphorylation of Gab1, it does appear to neg-
atively regulate the EGF-induced activation of PI-3 kinase
through an undefined mechanism. Finally we demon-
strate that ErbB3 is capable of recruiting PI-3 kinase in the
absence of Gab1, but Gab1 functions as the major media-
tor of PI-3 kinase activation in response to EGF
stimulation.
Results and Discussion
Previous studies have suggested that ErbB3 and Gab1 can
function as links between EGFR and PI-3 kinase. In this
report we use MEFs derived from Gab1 -/- embryos [19] to
explore the contribution of Gab1 and ErbB3 to EGF stim-
ulation of PI-3 kinase and Akt in these cells.
Gab1 is essential for EGF stimulation of PI-3 kinase and 
Akt
MEFs derived from Gab1-/- or wild type (WT) embryos
were stimulated with EGF and assayed for Gab1 tyrosine
phosphorylation, for activation of PI-3 kinase and for Akt
stimulation. As shown in Figure 1A, the endogenous Gab1
present in WT MEFs is tyrosine phosphorylated in
response to EGF treatment. As shown in Figure 1B, Gab1
-/- MEFs displayed very low levels of EGF-induced PI-3
kinase activity relative to cells expressing Gab1. We didBMC Biology 2004, 2:24 http://www.biomedcentral.com/1741-7007/2/24
Page 3 of 12
(page number not for citation purposes)
observe an approximate 2-fold increase in this low-level
basal PI-3 kinase activity in Gab1 -/- MEFs, which repre-
sents a Gab1-independent signaling pathway. Gab1 -/-
and WT MEFs were additionally stimulated with EGF and
the activation of Akt was analyzed by immunoblotting
with antibodies which recognize specifically the activated
form of Akt. As shown in Figure 1C (top and middle pan-
els), Gab1 -/- cells display no activation of Akt in response
to EGF, while WT MEFs show EGF-stimulated Akt activa-
tion within two minutes of EGF treatment.
The cDNA encoding the wild type murine Gab1 sequence
was cloned into a retroviral vector, and the virus was used
to infect Gab1 -/- MEFs. Stable cell lines were selected for
co-transduction of a puromycin resistance gene and pools
of selected cells were used for further analysis. As shown in
Figure 1A, the ectopic Gab1 protein was expressed at
slightly lower levels in the Gab1 -/- MEFs relative to endog-
enous Gab1 expression seen in the wild type MEFs. Quan-
titation by densitometry reveals Gab1 expression in wild
type MEFs to be 1.4-fold higher than ectopic Gab1
expression in Gab1 -/- MEFs. Treatment with EGF induced
Expression of wild type Gab1 rescues EGF-induced PI-3 kinase and Akt activation in Gab1 deficient MEFs Figure 1
Expression of wild type Gab1 rescues EGF-induced PI-3 kinase and Akt activation in Gab1 deficient MEFs. A. The indicated cell 
lines were serum-starved for 24 hours and stimulated with 10 ng/ml EGF for five minutes at 37°C. Cell extracts were prepared 
and analyzed for Gab1 tyrosine phosphorylation and Gab1 expression. Both WT MEFs and cells expressing exogenous Gab1 
show Gab1 tyrosine phosphorylation in response to EGF treatment. B. The indicated cell lines were serum-starved for 24 
hours and stimulated with 100 ng/ml EGF for five minutes at 37°C. Cell extracts were prepared and phosphotyrosine immuno-
precipitates were analyzed for PI-3 kinase activity. Gab1 -/- cells fail to show phosphotyrosine-associated PI-3 kinase activity, 
while cells expressing exogenous Gab1 display phosphotyrosine-associated PI-3 kinase activity that is augmented by EGF treat-
ment. C. The indicated cell lines were serum-starved for 24 hours and stimulated with 1 ng/ml EGF for varying periods of time 
at 37°C. Cell extracts were prepared and analyzed for activation of Akt by using antibodies that specifically recognize the 
serine473 phosphorylated form of Akt. Membranes were subsequently stripped and immunoblotted for Akt to confirm equal 
loading. Ectopic expression of Gab1 in Gab1 -/- MEFs rescues the EGF-induced activation of Akt.
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tyrosine phosphorylation of the exogenous Gab1 protein
expressed in the Gab1 -/- MEFs at levels similar to endog-
enous Gab1 in wild type MEFs. As shown in Figure 1B,
expression of exogenous Gab1 in the Gab1 -/- MEFs results
in Gab1-associated PI-3 kinase activity that is augmented
following EGF treatment. The low level of EGF-induced PI-
3 kinase activity observed in the Gab1 -/- cells may be due
to signaling via an alternate, Gab1-independent mecha-
nism. These cells were additionally treated with EGF over a
period of time and the activation of Akt was assayed by
immunoblotting with antibodies specific for the Ser473
phosphorylated form of Akt. The experiment presented in
Fig 1C shows that ectopic expression of Gab1 in the Gab1
deficient cells rescues EGF-induced Akt activation to levels
similar to those observed in EGF-treated wild type MEFs.
Taken together, these results demonstrate that Gab1 is
required for EGF-stimulation of PI-3 kinase and Akt.
The canonical p85 binding sites on Gab1 are essential for 
PI-3 kinase and Akt activation in response to EGF 
stimulation
The cDNA encoding a mutant Gab1 protein, containing
tyrosine to phenylalanine point mutations at the three
binding sites for the p85 regulatory subunit of PI-3 kinase
(Y446F/Y472F/Y589F) (Gab1F446/472/589), was cloned into
a retroviral vector and used to generate pools of stable MEF
cell lines as described above. We first assayed the cells for
Gab1 expression, and for the ability of the mutant
Gab1F446/472/589  protein to become tyrosine phosphor-
ylated in response to EGF treatment. As shown in Figure 2A,
both wild type Gab1 and Gab1F446/472/589 undergo tyrosine
phosphorylation in response to EGF treatment (upper left
panel). Quantitation of multiple experiments by densitom-
etry reproducibly demonstrates that Gab1F446/472/589 is tyro-
sine phosphorylated following EGF treatment to similar
levels when normalized for Gab1 expression levels. We
next subjected lysates from unstimulated or EGF stimulated
cells to immunoprecipitation with anti-Gab1 antibodies
followed by immunoblotting with anti-p85 antibodies. As
has been demonstrated previously [20], wild type Gab1
readily coimmunoprecipitated p85 following EGF treat-
ment, while the Gab1F446/472/589 mutant protein failed to
show an association with p85, confirming that the
Gab1F446/472/589 protein is deficient in p85 binding. Similar
levels of Gab1 expression in these cells were confirmed by
reprobing the Gab1 phosphotyrosine blot with anti-Gab1
antibodies (Figure 2A, bottom left panel). Additionally,
total cell lysates of all Gab1 expressing cell lines described
in this study were subjected to anti-Gab1 immunoblotting,
providing independent evidence for similar levels of Gab1
expression across all cell lines (Figure 2A, right panel).
Because the substrates of Shp2 are for the most part
unknown, we were additionally interested in examining
the state of EGFR tyrosine phosphorylation following treat-
ment with EGF in order to determine if the failure of Gab1
to bind p85, and potentially recruit Shp2, would influence
levels of EGFR autophosphorylation. However, stimulation
with EGF for varying time intervals revealed no significant
differences in the levels of autophosphorylation of EGFR in
cells expressing wild type Gab1 versus the Gab1F446/472/589
mutant (Figure 2B). A linear representation of the EGF-
induced EGFR tyrosine phosphorylation following normal-
ization for EGFR expression levels is shown in Figure 2B
(bottom). These results are consistent with our finding that
p85 binding to Gab1 does not influence the recruitment of
Shp2 to the Gab1 signaling complex, and are inconsistent
with the conclusion that Gab1 mediates a PI-3 kinase-
dependent recruitment of Shp2 [14].
We next explored the role of Gab1 in EGF-induced activa-
tion of the PI-3 kinase/Akt cell survival pathway utilizing
the Gab1F446/472/589expressing cells. We first assayed the
Gab1-associated PI-3 kinase activity directly through a PI-
3 kinase assay. As shown in Figure 2C, immunoprecipita-
tion of wild type Gab1 following EGF treatment brings
down associated PI-3 kinase activity. However immuno-
precipitation of Gab1F446/472/589 is not associated with sig-
nificant levels of PI-3 kinase in the presence or absence of
EGF stimulation. In order to assay the effects of EGF stim-
ulation on signaling downstream of PI-3 kinase, Gab1 -/-
MEFs expressing no Gab1, wild type Gab1 or Gab1F446/472/
589 were treated with EGF over varying times and cell
lysates were immunoblotted for serine-phosphorylated
Akt. Mutation of the p85 binding sites on Gab1 essentially
eliminated all EGF-induced Akt activation relative to cells
expressing wild type Gab1 (Figure 2D). The binding of
p85 is absolutely required for Gab1-mediated activation
of PI-3 kinase and Akt following EGF treatment [9].
Previous work has indicated that treatment of cells with PI-
3 kinase inhibitors reduces levels of EGF-induced complex
formation between Gab1 and the protein tyrosine phos-
phatase Shp2 [14]. This finding suggests a role for Gab1 in
the PI-3 kinase-dependent recruitment of Shp2 following
EGF stimulation. We have examined the possibility that
mutation of the p85 binding sites on Gab1, which prevents
PI-3 kinase activation, altered EGF-induced recruitment of
Shp2 as compared to the recruitment of Shp2 by wild type
Gab1. For this purpose, lysates from unstimulated or EGF-
stimulated cells were subjected to immunoprecipitation
with anti-Gab1 antibodies following immunoblotting with
anti-Shp2 antibodies. The experiment presented in Fig 2A
shows that mutation of the p85 binding sites on Gab1 did
not affect recruitment of Shp2 by Gab1 following EGF stim-
ulation (Figure 2A, fourth panel from the top). As has been
previously observed [20], we noted a low level of basal
association between Shp2 and both Gab1 and Gab1F446/
472/589, which may be due to incomplete growth factor star-
vation prior to EGF stimulation in these experiments.BMC Biology 2004, 2:24 http://www.biomedcentral.com/1741-7007/2/24
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Expression of a Gab1 mutant protein deficient in p85 binding fails to rescue EGF-induced PI-3 kinase/Akt activation in Gab1  deficient MEFs Figure 2
Expression of a Gab1 mutant protein deficient in p85 binding fails to rescue EGF-induced PI-3 kinase/Akt activation in Gab1 
deficient MEFs. A. The indicated cell lines were serum-starved for 24 hours and stimulated with 10 ng/ml EGF for five minutes 
at 37°C. Cell extracts were prepared and analyzed for Gab1 tyrosine phosphorylation, Gab1 co-immunoprecipitation with p85, 
p85 expression, Gab1 co-immunoprecipitation with Shp2, and Gab1 expression. Both Gab1 and Gab1F446/472/589 are tyrosine 
phosphorylated in response to EGF treatment, and both form a stable complex with Shp2. However, Gab1F446/472/589 fails to 
associate with the p85 subunit of PI-3 kinase. Additionally total cell lysates from the indicated cell lines were immunoblotted 
with anti-Gab1 antibodies, providing independent evidence that Gab1 is expressed at approximately equal levels in all cell lines. 
B. The indicated cell lines were serum-starved for 24 hours and stimulated with 10 ng/ml EGF for varying periods of time at 
37°C. Cell extracts were prepared and analyzed for EGFR tyrosine phosphorylation. All of the cell lines examined show similar 
kinetics of EGF-induced EGFR activation. Immunoblots were quantitated by densitometry, normalized for EGFR expression 
and represented linearly. Diamonds = Gab1 -/-, squares = Gab1, triangles = Gab1F446/472/589. C. The indicated cell lines were 
serum-starved for 24 hours and stimulated with 100 ng/ml EGF for five minutes at 37°C. Cell extracts were prepared and 
Gab1 immunoprecipitates were analyzed for PI-3 kinase activity. Ectopic expression of wild type Gab1 restored EGF-induced 
PI-3 kinase activity, while expression of Gab1F446/472/589 fails to rescue PI-3 kinase activity in response to EGF treatment. D. The 
indicated cell lines were serum-starved for 24 hours and stimulated with 1 ng/ml EGF for varying periods of time at 37°C. Cell 
extracts were prepared and analyzed for activation of Akt by using antibodies that specifically recognize the serine473-phos-
phorylated form of Akt. Membranes were subsequently stripped and immunoblotted for Akt to confirm equal loading. Ectopic 
expression of Gab1 in Gab1 -/- MEFs rescues activation of Akt in response to EGF treatment, while expression of Gab1F446/472/
589 fails to rescue the EGF-induced Akt activation.
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Expression of Gab1 mutant protein deficient in Shp2 
binding rescues EGF-induced PI-3 kinase/Akt activation in 
Gab1 -/- MEFs
To assess the role of the protein tyrosine phosphatase
Shp2 in Gab1-mediated signaling induced by EGF, two
Gab1 mutants were generated and expressed in pools of
Gab1 -/- MEFs. The first contained tyrosine to phenyla-
lanine point mutations at the two binding sites for the
Shp2 protein tyrosine phosphatase (Y627F/Y659F) (des-
ignated Gab1F627/659) and the second contained muta-
tions at the Shp2 binding sites as well as at the three PI-3
kinase binding sites described above (designated
Gab1F446/472/589/627/659). We first assayed the ability of the
mutant Gab1 proteins to become tyrosine phosphor-
ylated in response to EGF. As shown in Figure 3A (top
panel) both wild type Gab1 protein and the Gab1F627/659
protein readily undergo tyrosine phosphorylation when
stimulated with EGF. Quantitation following densitome-
try indicates that Gab1F627/659  is reproducibly tyrosine
phosphorylated to levels approximately 1.5-fold higher
than Gab1. This result suggests that Gab1 may be a sub-
strate of Shp2, and that blocking Shp2 binding thereby
increases EGF-induced Gab1 tyrosine phosphorylation.
The Gab1F446/472/589/627/659 mutant reproducibly displayed
lower levels of tyrosine phosphorylation following treat-
ment with EGF suggesting that these five tyrosines are the
main phosphorylation sites on Gab1.
Immunoprecipitation of cell lysates with anti-Gab1 anti-
bodies followed by immunoblotting with anti-Shp2 anti-
bodies demonstrates that wild type Gab1 forms a complex
with Shp2 following EGF treatment, while the Gab1F627/
659 mutant proteins fail to show an association with Shp2
thus confirming that phosphorylation of Tyr627 and 659
is required for Shp2 binding (Fig 3A). The basal interac-
tion we observed between Gab1 and Shp2 in the absence
of EGF stimulation (Figure 2A) is absent in the Gab1F627/
659 mutant, even following prolonged exposures of the
western blot.
We did not detect a change in the tyrosine phosphoryla-
tion of EGFR in cells expressing Gab1 proteins that are
deficient in recruitment of Shp2. The experiment pre-
sented in Fig 3B shows cells stimulated with EGF over var-
ying periods of time and cell extracts assayed for levels of
EGFR tyrosine autophosphorylation. As has been previ-
ously reported [15,18,20], recruitment of Shp2 by Gab1
does not alter the magnitude or kinetics of tyrosine auto-
phosphorylation of EGFR (Figure 3B, left panels). Levels
of EGFR autophosphorylation are represented linearly fol-
lowing quantitation by densitometry and normalization
for protein expression levels (Figure 3B, bottom).
Previous work with Shp2 -/- cells demonstrated an ele-
vated and sustained activation of PI-3 kinase and Akt in
response to EGF treatment, and it was proposed that Shp2
may act to dephosphorylate Gab1 at one or both of the
p85 binding sites [18]. We utilized the Gab1 proteins defi-
cient in Shp2 binding to assay more directly the role of the
Shp2-Gab1 complex in mediating activation of PI-3
kinase and Akt in response to EGF stimulation. As shown
in Figure 3C, immunoprecipitation of Gab1F627/659 brings
down 1.6-fold higher basal levels of PI-3 kinase activity
relative to wild type Gab1 as assayed by PIP3 production.
Importantly, Gab1 mutants defective for Shp2 binding
show approximately 2-fold higher Gab1-associated PI-3
kinase activity in response to EGF treatment. Consistent
with these findings, previous studies have demonstrated
that cells transiently over-expressing Gab1F627/659 bound
more p85 [18]. In both Gab1 and Gab1F627/659expressing
cells the Gab1-associated PI-3 kinase activity is aug-
mented by EGF treatment. As expected, the additional
mutation of the p85 binding sites eliminates Gab1-associ-
ated PI-3 kinase activity. In order to assay the effects of
EGF stimulation on signaling downstream of PI-3 kinase,
cells were treated with EGF for varying periods of time and
cell lysates were assayed for Akt activation by immunob-
lotting with P-Ser473 Akt antibodies. Interestingly, cells
expressing the Gab1F627/659 protein reproducibly showed
activation of Akt with significantly sustained kinetics rela-
tive to cells expressing wild type Gab1 (Figure 3D, left
panels). As expected, the additional mutation of the p85
binding sites (Gab1F446/472/589/627/659) limited Akt activa-
tion to levels similar to those observed in the Gab1 -/-
cells, confirming the requirement for PI-3 kinase associa-
tion with Gab1 to induce EGF-mediated activation of the
Akt pathway. Taken together, these results suggest a role
for Shp2 in negatively regulating the EGF induced activa-
tion of the PI-3 kinase pathway via Gab1, possibly by
dephosphorylating Gab1 at p85 binding sites.
Expression of ErbB3 in Gab1 -/- MEFs enhances activation 
of the PI-3 kinase signaling pathway
As described above, PI-3 kinase is recruited to the EGFR
via the adaptor protein Gab1. The results presented here
demonstrate that Gab1 is required for EGF-induced acti-
vation of the PI-3 kinase pathway via the EGFR, presuma-
bly because this receptor does not contain binding sites
for the p85 regulatory subunit of PI-3 kinase. The catalyt-
ically inactive ErbB3 receptor, however, contains at least
six binding sites for p85 [5], and thus may bypass the
requirement for Gab1 in response to EGF by heterodimer-
izing with the catalytically active EGFR. In order to test
this hypothesis, retroviral vectors were used to introduce
either the Gab1 or ErbB3 genes into Gab1 -/- MEFs that
endogenously express the EGFR but not ErbB3, and pools
of stable cell lines were selected for further analysis. We
first assayed the ability of the endogenous EGFR to be
tyrosine autophosphorylated in response to EGF, as well
as the ability of the exogenous ErbB3 receptor to beBMC Biology 2004, 2:24 http://www.biomedcentral.com/1741-7007/2/24
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Expression of a Gab1 mutant protein deficient in Shp2 binding enhances EGF-induced activation of the PI-3 kinase/Akt signaling  pathway Figure 3
Expression of a Gab1 mutant protein deficient in Shp2 binding enhances EGF-induced activation of the PI-3 kinase/Akt signaling 
pathway. A. The indicated cell lines were serum-starved for 24 hours and stimulated with 10 ng/ml EGF for five minutes at 
37°C. Cell extracts were prepared and analyzed for Gab1 tyrosine phosphorylation, Gab1-Shp2 co-immunoprecipitation and 
Gab1 expression. Gab1F627/659 becomes tyrosine phosphorylated in response to EGF treatment to levels approximately 1.5-fold 
higher than Gab1 as determined by densitometry, while Gab1F446/472/589/627/659 does not show EGF-induced tyrosine phosphor-
ylation in this assay. Wild type Gab1 forms a stable complex with Shp2 in response to EGF treatment, while Gab1F627/659 and 
Gab1F446/472/589/627/659 do not. B. The indicated cell lines were serum-starved for 24 hours and stimulated with 10 ng/ml EGF for 
varying periods of time at 37°C. Cell extracts were prepared and analyzed for EGFR tyrosine phosphorylation and EGFR 
expression. All of the cell lines examined show similar kinetics of EGF-induced EGFR activation. Immunoblots were quantitated 
by densitometry, normalized for EGFR expression, and represented linearly. Diamonds = Gab1 -/-, squares = Gab1, triangles = 
Gab1F627/659, circles = Gab1F446/472/589/627/659. C. The indicated cell lines were serum-starved for 24 hours and stimulated with 
100 ng/ml EGF for five minutes at 37°C. Cell extracts were prepared and Gab1 immunoprecipitates were analyzed for PI-3 
kinase activity. Cells expressing exogenous Gab1F627/659 display enhanced PI-3 kinase activity relative to cells expressing wild 
type Gab1. Expression of exogenous Gab1F446/472/589/627/659 fails to rescue EGF-induced PI-3 kinase activity in Gab1 deficient 
MEFs. D. The indicated cell lines were serum-starved for 24 hours and stimulated with 1 ng/ml EGF for varying periods of time 
at 37°C. Cell extracts were prepared and analyzed for activation of Akt by using antibodies that specifically recognize the 
serine473-phosphorylated form of Akt. Membranes were subsequently stripped and immunoblotted for Akt to confirm equal 
loading. Cells expressing exogenous Gab1F627/659 display enhanced activation of Akt with sustained kinetics relative to cells 
expressing wild type Gab1. Expression of exogenous Gab1F446/472/589/627/659 fails to rescue EGF-induced Akt activation in Gab1 
deficient MEFs.
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Figure 4 (see legend on next page)
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tyrosine phosphorylated in response to stimulation with
either EGF or neuregulin (NRG). The experiment pre-
sented in Fig 4A shows that all cell lines exhibit EGFR
autophosphorylation in response to EGF treatment (Fig-
ure 4A, upper left panel), while only cells expressing the
ectopically introduced ErbB3 protein show ErbB3 tyrosine
phosphorylation in response to EGF stimulation. Interest-
ingly, ErbB3 reproducibly shows constitutive low-level
tyrosine phosphorylation that is augmented only 1.3-fold
in response to EGF treatment. Cells expressing ErbB3
show tyrosine phosphorylation in response to treatment
with NRG (Figure 4A, upper and middle right panels).
Expression of EGFR and ErbB3 in the appropriate cell
lines was confirmed by immunoblotting with antibodies
specific for EGFR and ErbB3, respectively (Figure 4A,
lower panels). The apparent decrease in EGFR expression
in cells co-expressing EGFR and ErbB3 following EGF
treatment was not observed in repetitions of this experi-
ment, and is likely due to a stripping anomaly. Addition-
ally, we demonstrated that Gab1 -/- MEFs that express
wild type Gab1 display Gab1 tyrosine phosphorylation in
response to EGF treatment, while Gab1 -/- control cells or
those expressing ErbB3 do not show Gab1 phosphoryla-
tion (Figure 4B, upper panel).
In order to test the ability of ErbB3 to rescue the EGF-
induced activation of the PI-3 kinase/Akt signaling path-
way in Gab1 -/- MEFs, we first assayed these cells for EGF-
induced PI-3 kinase activity. Cells were either left unstim-
ulated or were stimulated with EGF and cell lysates were
immunoprecipitated with anti-phosphotyrosine anti-
body. Phosphotyrosine-associated PI-3 kinase activity was
then assayed by analysis of PIP3 production. As shown in
Figure 4C, both cells expressing wild type Gab1 and ErbB3
show PI-3 kinase activity, while Gab1 -/- cells do not.
Interestingly, EGF induces PI-3 kinase activity to a greater
degree in cells expressing Gab1 relative to cells expressing
ErbB3. In order to assay the effects of EGF stimulation on
signaling downstream of PI-3 kinase, cells were treated
with EGF over varying periods of time and assayed for the
presence of Ser473-phosphorylated Akt. Treatment of
cells expressing either wild type Gab1 or ErbB3 with EGF
induced rapid activation of Akt, although cells expressing
wild type Gab1 reproducibly displaed higher levels of
phosphorylated Akt with significantly sustained kinetics
relative to Gab1 -/- cells expressing ErbB3 (Figure 4D, left
panels). Equal loading and expression levels of Akt were
confirmed by immunoblotting (Figure 4D, right panels).
Cells expressing ErbB3 displayed activation of Akt in
response to treatment with NRG at levels similar to or
greater than that seen in Gab1-expressing cells following
EGF treatment, with activation reproducibly observed at
longer time points (Figure 4E, left panels). Again, equal
loading and expression levels of Akt were confirmed by
immunoblotting (Figure 4E, right panels). The
phosphorylation of AKT in cells expressing Gab1, which
shows modest enhancement following treatment with
NRG, may be attributed to alternate signaling pathways
including those mediated by ErbB2 and ErbB4. Involve-
ment of these receptors was not explored in this study.
Expression of ErbB3 in Gab1-deficient MEFs partially rescues EGF-induced activation of the PI-3 kinase/Akt signaling pathway Figure 4 (see previous page)
Expression of ErbB3 in Gab1-deficient MEFs partially rescues EGF-induced activation of the PI-3 kinase/Akt signaling pathway. 
A. The indicated cell lines were serum-starved for 24 hours and stimulated with 10 ng/ml EGF for five minutes at 37°C. Cell 
extracts were analyzed for EGFR tyrosine phosphorylation and EGFR expression, and for ErbB3 tyrosine phosphorylation and 
ErbB3 expression. Cells were additionally stimulated with 10 ng/ml NRG and cell extracts analyzed for ErbB3 tyrosine phos-
phorylation. The endogenous EGFR is tyrosine phosphorylated in response to EGF in all cell lines. ErbB3 exhibits weak consti-
tutive tyrosine phosphorylation that is enhanced by NRG treatment, but is not significantly enhanced by treatment with EGF. 
Selected bands were quantitated by densitometry to determine relative increase in growth factor-induced tyrosine phosphor-
ylation. B. The indicated cell lines were serum-starved for 24 hours and stimulated with 10 ng/ml EGF for five minutes at 37°C. 
Cell extracts were analyzed for Gab1 tyrosine phosphorylation and Gab1 expression. Cells rescued with wild type Gab1 
exhibit Gab1 tyrosine phosphorylation in response to EGF treatment, while Gab1 -/- cells and Gab1-deficient cells expressing 
ErbB3 do not. C. The indicated cell lines were serum-starved for 24 hours and stimulated with 100 ng/ml EGF for five minutes 
at 37°C. Cell extracts were prepared and phosphotyrosine immunoprecipitates were analyzed for PI-3 kinase activity. Expres-
sion of wild type Gab1 in Gab1-deficient MEFs rescues the EGF-induced PI-3 kinase activity. Gab1 deficient MEFs exogenously 
expressing ErbB3 exhibit PI-3 kinase activity that is largely EGF-independent. D. The indicated cell lines were serum-starved 
for 24 hours and stimulated with 1 ng/ml EGF for varying periods of time at 37°. Cell extracts were analyzed for activation of 
Akt by using antibodies that specifically recognize the phosphorylated form of Akt. Membranes were subsequently stripped and 
immunoblotted for Akt to confirm equal loading. Ectopic expression of ErbB3 in Gab1 deficient cells results in a partial rescue 
of EGF-induced Akt activation relative to cells expressing wild type Gab1. E. The indicated cell lines were serum-starved for 24 
hours and stimulated with 1 ng/ml NRG for varying periods of time at 37°C. Cell extracts were analyzed for activation of Akt 
by using antibodies that specifically recognize the phosphorylated form of Akt. Membranes were subsequently stripped and 
immunoblotted for Akt to confirm equal loading. Treatment of Gab1-deficient cells exogenously expressing ErbB3 with NRG 
results in a robust and sustained activation of Akt, while cells expressing exogenous Gab1 do not exhibit Akt activation in 
response to NRG treatment.BMC Biology 2004, 2:24 http://www.biomedcentral.com/1741-7007/2/24
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Taken together, these results demonstrate that ErbB3 can
partially compensate for Gab1 deficiency in EGF-induced
activation of the PI-3 kinase/Akt signaling pathway,
although Gab1-mediated activation appears to be more
robust, and likely represents the primary mechanism by
which EGF stimulates PI-3 kinase and Akt. While ErbB3 is
relatively ineffective at mediating EGF-stimulation of PI-3
kinase activation, it is an efficient mediator of PI-3 kinase
stimulation in response to NRG stimulation. Thus, EGF
and NRG can stimulate PI-3 kinase activation in normal
and transfected cells by means of Gab1 and ErbB3,
respectively.
Conclusions
The results presented here demonstrate an absolute
requirement for Gab1 in EGF-induced activation of the PI-
3 kinase/Akt signaling pathway. Using this approach we
demonstrated a strict requirement for association between
Gab1 and p85 in EGF-induced PI-3 kinase activation, sug-
gesting that Gab1 indeed provides an essential link
between the EGFR and PI-3 kinase. Additionally, p85
binding does not play a significant role in Shp2 recruit-
ment to the EGFR-Gab1 signaling complex, in contrast to
previous studies [14]. We further demonstrated that the
Gab1-Shp2 complex is responsible for the negative regu-
lation of the strength and duration of PI-3 kinase/Akt sig-
naling in response to EGF previously observed in Shp2 -/-
cells. ErbB3 expression can bypass the requirement for
Gab1 in EGFR signaling and can partially rescue EGF-
induced activation of the PI-3 kinase/Akt cell survival
pathway. This alternate pathway to PI-3 kinase activation
may provide cells with a means of controlling either the
strength or duration of PI-3 kinase signaling through dif-
ferential expression of Gab1 and ErbB3, since the ErbB3-
mediated response appears to be weaker. Thus Gab1 plays
an essential role in bringing together a multi-protein sign-
aling complex in response to EGF that modulates a critical
aspect of cellular survival.
Methods
Expression constructs
Expression vectors for wild type Gab1 and for Gab1∆p85
(Y446F/Y472F/Y589F) were previously described [21].
The cDNAs of Gab1 (pcDNA3-Gab1-WT), Gab1F446/472/
589  (pcDNA3-Gab1-3YF), and ErbB3 (pcDNA3-ErbB3)
were subcloned into the mammalian retroviral vector
pBabe containing a gene for puromycin resistance. The
Gab1F627/659  and Gab1F446/472/589/627/659  mutants were
generated by site-directed mutagenesis (Strategene) car-
ried out on pBabe-Gab1-WT (to generate Gab1F627/659) or
pBabe-Gab1F446/472/589  (to generate Gab1F446/472/589/627/
659) according to the manufacturers' specifications.
Cell lines and culture
Gab1-deficient (Gab1 -/-) mouse embryonic fibroblasts
(MEFs) were obtained from Walter Birchmeier [22]. Wild
type or Gab1-/- MEFs were maintained in DMEM supple-
mented with 10% fetal bovine serum (Gibco), 2 mM L-
glutamine (Gibco), and 100 µg each of penicillin and
streptomycin. The retroviral vectors described above
(pBabe, pBabe-Gab1, pBabe-Gab1-Gab1F446/472/589,
pBabe-Gab1-Gab1F627/659, pBabe-Gab1-Gab1F446/472/589/
627/659, and pBabe-ErbB3) were used to transfect the
amphitropic retroviral packaging cell line GPG (obtained
from Joan Brugge) and high-titer viral stocks were used to
infect Gab1 -/- MEFs. Cells were selected in medium sup-
plemented with puromycin and pools of selected cells
were used for further experiments. Prior to stimulation
with EGF, cells were starved in serum-free medium.
Immunoprecipitation and immunoblotting
Cells were grown on 15-cm plates as described above to
approximately 80% confluence and then starved over-
night in DMEM without serum. Cells were left unstimu-
lated or were stimulated with recombinant human EGF
(Invitrogen) as indicated. Stimulations were halted by the
addition of ice-cold PBS. Cells were washed in PBS and
lysed in buffer containing 1% Triton X-100 as previously
described [23]. For Gab1 immunoprecipitations, a mix-
ture of polyclonal antibodies directed against both the N-
and C-termini of Gab1 and cross-linked to Protein A
Sepharose (Zymed) was incubated with cell extracts for 2–
4 hours at 4°C. For p85 immunoprecipitations, a mixture
of polyclonal antibodies directed against the N-terminal
SH2 domain of p85 and the full-length p85 protein
(Upstate) was incubated with cell extracts for 2–4 hours at
4°C. For EGFR immunoprecipitations, a polyclonal anti-
body directed against the C-terminus of the EGFR was
incubated with cell extracts overnight at 4°C. For ErbB3
immunoprecipitations, a mixture of polyclonal antibod-
ies directed against both the N- and C-termini of ErbB3
was incubated with cell extracts overnight at 4°C. Protein
A Sepharose was added to immunoprecipitates (except
anti-Gab1) and incubated for 1 hour at 4°C. Immunopre-
cipitates were then washed in buffer containing 0.1% Tri-
ton X-100, separated by SDS/PAGE, and transferred to
nitrocellulose membranes (Bio-Rad). For Akt immunob-
lotting, total cell extracts were separated directly by SDS/
PAGE and transferred to nitrocellulose membranes. Mem-
branes were blocked for 1 hour or overnight in 5% BSA/
TBS and immunoblotted as indicated. The anti-phospho-
tyrosine blotting was carried out with antibody 4G10
(Upstate). Anti-Gab1, anti-EGFR and anti-ErbB3 blotting
was performed with the indicated polyclonal antibodies
(Upstate). Anti-Shp2 blotting was carried out with
polyclonal antibody (Santa Cruz). Anti-phosphoSer473-
Akt and anti-Akt blotting were performed with the respec-
tive polyclonal antibodies (Cell Signaling Technology).BMC Biology 2004, 2:24 http://www.biomedcentral.com/1741-7007/2/24
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Proteins were visualized by incubation with Enhanced
Chemiluminescence (Amersham Pharmacia) according to
the manufacturer's specifications.
PI-3 kinase assay
The PI-3 kinase assay was performed essentially as previ-
ously described [22-24]. Briefly, cells were serum-starved
for 24 hours and stimulated with EGF as indicated, and
cell extracts were prepared as described above. The lysates
were immunoprecipitated using anti-Gab1 polyclonal
antibodies or the monoclonal anti-phosphotyrosine anti-
body PY20 (Santa Cruz) for 2 hours at 4°C. Protein A
Sepharose was incubated with immunoprecipitates for 1
hour at 4°C. The immunoprecipitates were washed three
times with Buffer 1 (1X PBS, 1% NP-40), twice with Buffer
2 (0.5 M LiCl, 0.1 M Tris pH 7.5), twice with TNE (10 mM
Tris pH 7.5, 100 mM NaCl, 1 mM EDTA pH 8.0), and
twice with Buffer 4 (20 mM Hepes pH 7.5, 50 mM NaCl,
5 mM EDTA pH 8.0, 0.03% NP-40, 30 mM Tatrasodium
Pyrophosphate (Sigma)). L-α-Phosphatidylinositol
(Sigma) was added (10 µl of a sonicated solution at 10
mg/ml in 20 mM HEPES pH 7.5) and the reaction was ini-
tiated by the addition of 50 µl of the kinase buffer (20 mM
Tris pH 7.5, 75 mM NaCl, 10 mM MgCl2 10 µM ATP, 100
mM adenosine, 10 µCi [γ-32P] ATP) per sample. Samples
were incubated at 30°C for 15 minutes, and the reaction
was stopped by addition of 100 µl 1N HCl. Samples were
extracted by addition of 200 µl CHCl3/CH3OH (1:1). The
samples were vortexed and centrifuged, and the lower
organic phases containing phospholipids were dried at
27°C for two hours. Samples were resuspended in 10 µl
of PI-4-P standard (0.5 ml CHCl3, 0.5 ml CH3OH, 2.5 µl
HCl, 1 mg L-α-Phosphatidylinositol 4-monophosphate
(Sigma)) and subjected to thin layer chromatography
(TLC plates – VWR) in CHCl3/CH3OH/NH4OH/H2O
(45:35:7:3). The TLC plates were exposed in a Phos-
phorImager cassette for four days.
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